Lynx1 Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.59M Buy
1,562,093
+1,040,680
+200% +$1.97M 0.4% 10
2026
Q2
$970K Buy
521,413
+452,927
+661% +$746K 0.11% 15
2026
Q1
$111K Hold
68,486
– – 0.02% 21
2025
Q4
$138K Buy
+68,486
New +$160K 0.03% 21

Other funds holding PRQR

Lynx1 Capital Management's PRQR Position: Q3 2026 in Review

Lynx1 Capital Management increased its ProQR Therapeutics (PRQR) stake by 200% in Q3 2026, buying an estimated $1.97M and bringing the position to 1,562,093 shares worth $2.59M. The position accounts for 0.4% of the portfolio, ranked #10.

Lynx1 Capital Management first reported a position in PRQR in Q4 2025 and has held it in 4 quarters since. 73 funds tracked by Wall St. Rank hold PRQR as of Q3 2026.

  • Lynx1 Capital Management held 1,562,093 shares of ProQR Therapeutics worth $2.59M as of Q3 2026.
  • Lynx1 Capital Management bought 1,040,680 ProQR Therapeutics shares in Q3 2026, an estimated $1.97M.
  • ProQR Therapeutics made up 0.4% of Lynx1 Capital Management's portfolio in Q3 2026, its #10 holding.
  • Lynx1 Capital Management first reported a position in ProQR Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 73 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2026.

Based on Lynx1 Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.